BNIP3L Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population featuring targeted disruption of the BNIP3L gene in the HAP1 near-haploid human cell line. This product is supplied as a polyclonal pool, enabling researchers to interrogate the functional consequences of BNIP3L loss in a genetically defined, isogenic background without requiring single-cell cloning.
The HAP1 host cell line is a fibroblast-like, adherent near-haploid cell line derived from the KBM-7 chronic myeloid leukemia lineage. Its near-haploid karyotype facilitates straightforward CRISPR/Cas9-mediated gene disruption, as a single targeting event can suffice to generate functional knockout alleles, making it an ideal platform for loss-of-function studies in cancer biology, signal transduction, and drug discovery.
BNIP3L encodes a pro-apoptotic BH3-only protein and mitophagy receptor that orchestrates the selective elimination of mitochondria during hypoxia and erythroid differentiation. Transcriptionally activated by HIF1A, GATA1, FOXO3, and TP53, BNIP3L integrates stress signals to promote mitophagy by binding MAP1LC3A and GABARAP on autophagosomes, while simultaneously antagonizing BCL2 and BCL2L1 to derepress the intrinsic apoptotic pathway. Downstream, this leads to activation of BAX, CASP9, and CASP3. Interactions with BECN1 and DNM1L further link BNIP3L to autophagy initiation and mitochondrial fission, positioning it at the nexus of mitophagy and apoptosis. Representative pathway components include HIF1A, BNIP3L, BECN1, ATG5, MAP1LC3A, GABARAP, PINK1, PARK2, BAX, and CASP9.
In the HAP1 background, disruption of BNIP3L provides a powerful tool for dissecting its dual roles in mitophagy and apoptosis. The near-haploid nature of HAP1 cells ensures robust loss of BNIP3L expression in the polyclonal knockout population, allowing for unambiguous attribution of phenotypic effects to BNIP3L deficiency. This model is particularly valuable for studying hypoxia-induced mitophagy, apoptosis regulation, and erythropoiesis-related mitochondrial clearance, as well as for screening genetic interactors and chemical modulators of these processes.
Typical applications include mitophagy flux assays, mitochondrial membrane potential analysis with JC-1, co-immunoprecipitation of BNIP3L complexes, and Annexin V-based apoptosis detection. Combined with RNA-seq or RT-qPCR, these cells enable dissection of transcriptional networks governing mitophagy and apoptosis. They also serve as a platform for drug screens targeting mitophagy and apoptosis in cancer, neurodegeneration, and cardiovascular diseases. For further details, please contact Ascent Research.
